Literature DB >> 2707170

Growth stimulation of T47D human breast cancer cells by the anti-progestin RU486.

R T Bowden1, J R Hissom, M R Moore.   

Abstract

Our laboratory has previously reported that physiological levels of progestins stimulate growth of the human breast cancer cell line T47D. We have also determined that the antiprogestin RU486 inhibits this stimulation. Here we present the unexpected finding that RU486 alone also stimulates growth of these breast cancer cells. Thus, RU486 exhibits both antagonist and agonist-like activity, in a manner somewhat reminiscent of the antiestrogen tamoxifen. To our knowledge, this is the first report of stimulation of breast cancer growth by RU486.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2707170     DOI: 10.1210/endo-124-5-2642

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes.

Authors:  E A Musgrove; C S Lee; R L Sutherland
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

2.  Progestin stimulation of manganese superoxide dismutase and invasive properties in T47D human breast cancer cells.

Authors:  Aaron K Holley; Kelley K Kiningham; Douglas R Spitz; Dean P Edwards; Jeffrey T Jenkins; Michael R Moore
Journal:  J Steroid Biochem Mol Biol       Date:  2009-06-27       Impact factor: 4.292

3.  Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells.

Authors:  C Hurd; K Nag; N Khattree; P Alban; S Dinda; V K Moudgil
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

4.  Effects of antiprogestins on the rate of proliferation of breast cancer cells.

Authors:  K Iwasaki; B Underwood; M Herman; S Dinda; S Kodali; H J Kloosterboer; C Hurd; V K Moudgil
Journal:  Mol Cell Biochem       Date:  1999-08       Impact factor: 3.396

Review 5.  Steroid hormone receptors as prognostic markers in breast cancer.

Authors:  Maggie C Louie; Mary B Sevigny
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

6.  Antioxidant: a new role for RU-486 and related compounds.

Authors:  S Parthasarathy; A J Morales; A A Murphy
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 7.  Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use.

Authors:  G R Jang; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1997-12

Review 8.  Effects of omega-3 fatty acids on progestin stimulation of invasive properties in breast cancer.

Authors:  Michael R Moore; Rebecca A King
Journal:  Horm Cancer       Date:  2012-07-26       Impact factor: 3.869

Review 9.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

10.  CCM signaling complex (CSC) couples both classic and non-classic Progesterone receptor signaling.

Authors:  Johnathan Abou-Fadel; Xiaoting Jiang; Brian Grajeda; Akhil Padarti; Cameron C Ellis; Esmeralda Flores; Alyssa-Marie D Cailing-De La O; Jun Zhang
Journal:  Cell Commun Signal       Date:  2022-08-15       Impact factor: 7.525

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.